Sound Pharmaceuticals and Oxford collaborate on a new treatment for bipolar disorder

By Home Page
Seattle, WA and Oxford, England

Sound Pharmaceuticals (SPI) will collaborate with the University of Oxford on a Phase 2 clinical trial to test SPI-1005 for the treatment of bipolar disorder. Bipolar disorder is a psychiatric illness that involves both periods of mania and depression, and affects approximately one percent of adults worldwide. Unfortunately, patients have relatively few treatment options, often involving drugs such as lithium, which has significant side effects. Read More

David Guyer visionary biotech leader joins Sound Pharmaceuticals

By Home Page
Sound Pharmaceuticals is pleased to announce that David Guyer, MD has joined the company as a strategic advisor. Dr. Guyer is an accomplished academic ophthalmologist and an industry leader in the area of vision loss research and retinal drug development. Dr. Guyer is currently the Co-Founder, Chief Executive Officer and Chairman of Ophthotech which he began in 2007. As CEO, Dr. Guyer raised more than $350 million in financing including a $192 million IPO in 2013 and has advanced the lead program into Phase 3 clinical trials.

Read More

The World Health Organization reports 1.1 Billion teens and young adults at risk

By Home Page

(CNN) “Hey dude — can you turn your music down?”

If anyone says this to you while you’re wearing your earbuds, take note: You are probably endangering your hearing.

More than one billion teens and young adults are at risk of losing their hearing, according to WHO (that’s the World Health Organization, not the rock band).

It’s not just old folks who suffer hearing loss. Just by listening to music at what you probably think is a normal level, or hanging out in loud bars, nightclubs and music and sporting events, you can permanently damage your hearing.

Full Article here: